Smith & Nephew

Sports medicine leads a good Q3 showing

26/11/19 -"Smith & Nephew reported Q3 19 top-line growth of 4% on an underlying basis – driven by Sports Medicine Joint Repair (+12.2%), Advanced Wound Devices (+15.4%), Knee Implants (+4.6%) and ENT ..."

PDF page sample
Pages
66
Language
English
Published on
26/11/19
Download
You may also be interested by these reports :
04/09/26
Bastide ended FY25/26 above its revenue target, with Q4 organic growth recovering as the VPH headwind faded, confirming the one-off nature of the ...
01/09/26
We have resumed our coverage of the Tecan Group, updating the company’s accounts and our forecasts. The share price has gained strong momentum since ...
01/09/26
Dräger’s final Q2 26 results confirmed margin acceleration across both divisions, alongside a sharp improvement in FCF and net debt. The key ...
27/08/26
Elekta’s Q1 sales fell short of expectations, although profitability surpassed forecasts. The top line declined due to underperformance in Solutions, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO